|
25 Jun 2016
|
Pharmaceuticals & Biotech.
|
Phillip Capital
|
|
|
|
|
|
|
|
INR/EUR, and INR/USD) could have some minor impact on Indian pharma. GBP/EUR have depreciatedby8.9%/2.6%againsttheINRduetoBrexit,whiletheINRhasdepreciated1.2% againsttheUSD.AdversecurrencyfluctuationsintheGBPandEURarealmostneutralisedby...
|
|
15 Jun 2016
|
Pharmaceuticals & Biotech.
|
ICICI Securities Limited
|
|
|
|
|
Neutral
|
|
|
For Q4FY16, the I-direct pharma universe registered YoY revenue growth of 17.1% to | 36766.2 crore, driven by 27.8% YoY growth to | 11785.7 in the US and 14.4% YoY growth to | 7135.7 crore in domestic formulations...
|
|
17 May 2016
|
Pharmaceuticals & Biotech.
|
ICICI Securities Limited
|
|
|
|
|
|
|
|
Sun Pharma reported positive results for Phase III trials of psoriasis treatment novel biological molecule MK3222 (Tildrakizumab) in the US. Total ~1,800 patients were enrolled across 200 sites for MK3222....
|
|
16 Mar 2016
|
Pharmaceuticals & Biotech.
|
ICICI Securities Limited
|
|
|
|
|
|
|
|
ICICI Securities Ltd. | Retail Equity Research In an unprecedented move, the Health Ministry has banned 344 fixed dosage combinations (FDCs) drugs over safety concerns. In 2014, the...
|
|
07 Sep 2015
|
Pharmaceuticals & Biotech.
|
Phillip Capital
|
|
|
|
|
Sell
|
|
|
from ~45% earlier. R&D; spend relates to developing complex/specialty generics including (1) difficult formulation technologies (liposomes/nanoparticles/microspheres), (2) difficult tosynthesise/scale up (peptides, heparins, chiral chemistry), (3) differentiated delivery...
|
|
04 Sep 2015
|
Pharmaceuticals & Biotech.
|
Phillip Capital
|
|
|
|
|
Sell
|
|
|
from ~45% earlier. R&D; spend relates to developing complex/specialty generics including (1) difficult formulation technologies (liposomes/nanoparticles/microspheres), (2) difficult tosynthesise/scale up (peptides, heparins, chiral chemistry), (3) differentiated delivery...
|
|
17 Dec 2014
|
Pharmaceuticals & Biotech.
|
Reliance Securities
|
|
|
|
|
|
|
|
Sharp depreciation in Russia/CIS is likely to impact the near term growth prospects of select Indian pharma companies under our pharma universe. Of the total 6 companies that has meaningful exposure in terms of sales to Russia/CIS are Dr Reddy's (14%), Glenmark (8%), JB Chemicals (9%), Torrent Pharma (2%), Ipca Labs (6%) and Ranbaxy (5%). We analyze the impact of Ruble to our earnings estimate and would remain cautious if the currency depreciation continues. As per our analysis, the impact on earnings at current levels will be higher for JB Chemicals (7%), Dr Reddy's (5.5%) and Glenmark (2.7%)....
|